Rapid, Point-of-Need Diagnostic for Sexually Transmitted Infections

性传播感染的快速、按需诊断

基本信息

  • 批准号:
    10268054
  • 负责人:
  • 金额:
    $ 29.76万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-04-23 至 2023-03-31
  • 项目状态:
    已结题

项目摘要

Project Summary Over 370 million people worldwide are infected with the sexually transmitted infections (STIs) chlamydia, gonorrhea, and trichomoniasis each year. While treatable, delayed treatment can have serious health problems, including infertility, disseminated infection, and pregnancy complications. Since fewer than half of at-risk individuals are screened for these common STIs, it is necessary to destigmatize STI testing and bring rapid point-of-care STI diagnostics to the developed and especially to the developing world, where over 75% of STI cases are thought to occur. Current nucleic acid-based STI tests offer optimal sensitivity and specificity but require laboratory infrastructure (electricity, refrigeration, and trained laboratory technicians) that is largely lacking where these STIs are most prevalent. These tests take days to return a result, which can result in loss of patient to follow-up and treatment. In addition, these tests fail to track the occurrence of antibiotic-resistant gonorrhea. With increases in azithromycin and ciprofloxacin resistance, and more frequent reports of cephalosporin resistance, multidrug- resistant gonorrhea could become a serious threat to global health, necessitating susceptibility testing and antibiotic stewardship. In this SBIR project, GoDx, Inc. proposes to develop a rapid, hand-held, low-cost, and sensitive point-of-care diagnostic to deliver rapid STI test results, which would simplify screening and allow for immediate treatment at the initial visit. To develop a rapid test for chlamydia, gonorrhea, and trichomoniasis, we will focus on innovations to integrate nucleic acid extraction, amplification, and detection to develop and test a prototype device by the end of Phase II. Our easy-to-use sample preparation device would require fewer than three user steps to purify nucleic acids for downstream detection. We will also reach benchmarks for the sensitive and specific amplification of genetic markers in Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis using an isothermal amplification technique followed by lateral flow detection. Our test will also amplify genetic predictors of antibiotic susceptibility to aid in the tracking and treatment of antibiotic resistant gonorrhea. Finally, we will integrate our assays into a test device delivering both STI and AMR test results in 30 minutes, with performance on par with laboratory-based STI tests. Our diagnostic tool will be simple and low-cost, making it ideal for use in the developing world where laboratory infrastructure is lacking, affordable for better screening programs worldwide, and easy enough for eventual in-home testing.
项目摘要 全世界有超过3.7亿人感染性传播感染(STIs) 衣原体淋病和滴虫病虽然可以治疗,但延迟治疗可能 有严重的健康问题,包括不孕症、传播性感染和怀孕 并发症由于只有不到一半的高危人群接受了这些常见性传播感染的筛查, 有必要消除STI测试的污名,并将快速的护理点STI诊断带到 发达国家,特别是发展中国家,超过75%的性传播感染病例被认为是 发生.目前基于核酸的STI测试提供了最佳的灵敏度和特异性,但需要 实验室基础设施(电力、制冷和训练有素的实验室技术人员), 在这些性传播感染最普遍的地方基本上缺乏。这些测试需要几天时间才能得出结果, 这可能导致患者失访和治疗。此外,这些测试无法跟踪 耐药淋病的发生。随着阿奇霉素的增加, 环丙沙星耐药,头孢菌素耐药的报告更频繁,多药- 耐药性淋病可能成为全球健康的严重威胁, 测试和抗生素管理。在这个SBIR项目中,GoDx,Inc.建议开发一个快速, 手持式、低成本、灵敏的床旁诊断,提供快速的STI检测结果, 这将简化筛查并允许在初次就诊时立即治疗。发展 衣原体、淋病和滴虫病的快速检测,我们将专注于创新, 集成核酸提取、扩增和检测以开发和测试原型 第二阶段结束时的设备。我们易于使用的样品制备设备将需要更少的 而不是三个用户步骤来纯化用于下游检测的核酸。我们也将达到 奈瑟氏菌遗传标记敏感性和特异性扩增的基准 淋病、沙眼衣原体和阴道毛滴虫, 扩增技术,然后进行侧向流检测。我们的测试也会放大基因 抗生素敏感性的预测因子,以帮助跟踪和治疗抗生素耐药 淋病最后,我们将把我们的检测方法整合到一个同时提供STI和AMR的测试设备中。 测试结果在30分钟内,性能与基于实验室的STI测试相当。我们 诊断工具将是简单和低成本的,使其成为发展中国家的理想选择, 缺乏实验室基础设施,无法负担全球范围内更好的筛查项目, 这对于最终的家庭测试来说足够简单。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Chang Hee Kim其他文献

Chang Hee Kim的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Chang Hee Kim', 18)}}的其他基金

Rapid and Simple Paper Strip Test for the Multiplexed Detection of Gastrointestinal Pathogens at the Point-of-Need
快速、简单的纸条测试,用于在需要时多重检测胃肠道病原体
  • 批准号:
    10255421
  • 财政年份:
    2020
  • 资助金额:
    $ 29.76万
  • 项目类别:
Rapid, Handheld, Point-of-Care Stool Sample-prep Device for the Extraction and Detection of Nucleic Acid from Diarrheal Pathogens
用于从腹泻病原体中提取和检测核酸的快速、手持式护理点粪便样本制备装置
  • 批准号:
    10086785
  • 财政年份:
    2020
  • 资助金额:
    $ 29.76万
  • 项目类别:
Rapid, Handheld, Point-of-Care Stool Sample-prep Device for the Extraction and Detection of Nucleic Acid from Diarrheal Pathogens
用于从腹泻病原体中提取和检测核酸的快速、手持式护理点粪便样本制备装置
  • 批准号:
    10611784
  • 财政年份:
    2020
  • 资助金额:
    $ 29.76万
  • 项目类别:
One-Step In Situ RNA Integrity Analysis for FFPE Tissue
FFPE 组织的一步原位 RNA 完整性分析
  • 批准号:
    8200295
  • 财政年份:
    2011
  • 资助金额:
    $ 29.76万
  • 项目类别:

相似海外基金

Ecological and Evolutionary Drivers of Antibiotic Resistance in Patients
患者抗生素耐药性的生态和进化驱动因素
  • 批准号:
    EP/Y031067/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.76万
  • 项目类别:
    Research Grant
Collaborative Research: Leveraging the interactions between carbon nanomaterials and DNA molecules for mitigating antibiotic resistance
合作研究:利用碳纳米材料和 DNA 分子之间的相互作用来减轻抗生素耐药性
  • 批准号:
    2307222
  • 财政年份:
    2024
  • 资助金额:
    $ 29.76万
  • 项目类别:
    Standard Grant
Collaborative Research: Leveraging the interactions between carbon nanomaterials and DNA molecules for mitigating antibiotic resistance
合作研究:利用碳纳米材料和 DNA 分子之间的相互作用来减轻抗生素耐药性
  • 批准号:
    2307223
  • 财政年份:
    2024
  • 资助金额:
    $ 29.76万
  • 项目类别:
    Standard Grant
Molecular Epidemiology of Antibiotic Resistance in Clostridioides difficile
艰难梭菌抗生素耐药性的分子流行病学
  • 批准号:
    502587
  • 财政年份:
    2024
  • 资助金额:
    $ 29.76万
  • 项目类别:
The roles of a universally conserved DNA-and RNA-binding domain in controlling MRSA virulence and antibiotic resistance
普遍保守的 DNA 和 RNA 结合域在控制 MRSA 毒力和抗生素耐药性中的作用
  • 批准号:
    MR/Y013131/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.76万
  • 项目类别:
    Research Grant
Determining structural dynamics of membrane proteins in their native environment: focus on bacterial antibiotic resistance
确定膜蛋白在其天然环境中的结构动力学:关注细菌抗生素耐药性
  • 批准号:
    MR/X009580/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.76万
  • 项目类别:
    Fellowship
CAREER: Systems Microbiology and InterdiscipLinary Education for Halting Environmental Antibiotic Resistance Transmission (SMILE HEART)
职业:阻止环境抗生素耐药性传播的系统微生物学和跨学科教育(SMILE HEART)
  • 批准号:
    2340818
  • 财政年份:
    2024
  • 资助金额:
    $ 29.76万
  • 项目类别:
    Continuing Grant
Reinforcing the battle at the bacterial cell wall: Structure-guided characterization and inhibition of beta-lactam antibiotic resistance signalling mechanisms
加强细菌细胞壁的战斗:β-内酰胺抗生素耐药信号机制的结构引导表征和抑制
  • 批准号:
    480022
  • 财政年份:
    2023
  • 资助金额:
    $ 29.76万
  • 项目类别:
    Operating Grants
The spread of antibiotic resistance in bacteria-plasmid networks
抗生素耐药性在细菌-质粒网络中的传播
  • 批准号:
    BB/X010473/1
  • 财政年份:
    2023
  • 资助金额:
    $ 29.76万
  • 项目类别:
    Fellowship
An RNA Nanosensor for the Diagnosis of Antibiotic Resistance in M. Tuberculosis
用于诊断结核分枝杆菌抗生素耐药性的 RNA 纳米传感器
  • 批准号:
    10670613
  • 财政年份:
    2023
  • 资助金额:
    $ 29.76万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了